QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Forecast, Price & News

$5.32
-0.43 (-7.48%)
(As of 05/30/2023 ET)
Compare
Today's Range
$5.30
$5.77
50-Day Range
$5.32
$6.79
52-Week Range
$1.77
$8.69
Volume
158,512 shs
Average Volume
174,963 shs
Market Capitalization
$223.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Verrica Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.5% Upside
$10.67 Price Target
Short Interest
Bearish
7.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.94mentions of Verrica Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.96) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

558th out of 1,009 stocks

Pharmaceutical Preparations Industry

272nd out of 494 stocks


VRCA stock logo

About Verrica Pharmaceuticals (NASDAQ:VRCA) Stock

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
NOVN: NDA Submitted
Verrica Flat on Forwarding NDA to FDA
See More Headlines
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Company Calendar

Last Earnings
5/09/2023
Today
5/30/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRCA
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+100.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-24,490,000.00
Net Margins
-261.70%
Pretax Margin
-261.70%

Debt

Sales & Book Value

Annual Sales
$8.64 million
Book Value
$0.97 per share

Miscellaneous

Free Float
24,545,000
Market Cap
$223.21 million
Optionable
Not Optionable
Beta
1.99

Key Executives

  • Ted WhiteTed White
    President, Chief Executive Officer & Director
  • Terence Kohler
    Chief Financial Officer
  • Gary Goldenberg
    Chief Medical Officer
  • Eugene Scavola
    Executive Vice President-Technical Operations
  • Christopher G. HayesChristopher G. Hayes
    Secretary, Chief Legal & Compliance Officer













VRCA Stock - Frequently Asked Questions

Should I buy or sell Verrica Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRCA shares.
View VRCA analyst ratings
or view top-rated stocks.

What is Verrica Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 12-month price objectives for Verrica Pharmaceuticals' shares. Their VRCA share price forecasts range from $10.00 to $11.00. On average, they anticipate the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 100.5% from the stock's current price.
View analysts price targets for VRCA
or view top-rated stocks among Wall Street analysts.

How have VRCA shares performed in 2023?

Verrica Pharmaceuticals' stock was trading at $2.75 at the beginning of the year. Since then, VRCA shares have increased by 93.5% and is now trading at $5.32.
View the best growth stocks for 2023 here
.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,780,000 shares, an increase of 21.1% from the April 30th total of 1,470,000 shares. Based on an average daily volume of 163,600 shares, the days-to-cover ratio is currently 10.9 days. Approximately 7.1% of the company's stock are short sold.
View Verrica Pharmaceuticals' Short Interest
.

When is Verrica Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VRCA earnings forecast
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. The company earned $0.04 million during the quarter. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 50.33% and a negative net margin of 261.70%.

What other stocks do shareholders of Verrica Pharmaceuticals own?
When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (6.32%), FMR LLC (3.25%), Geode Capital Management LLC (0.43%), BML Capital Management LLC (0.36%), Jane Street Group LLC (0.32%) and Miracle Mile Advisors LLC (0.28%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, John A Stalfort III, Paul B Manning, Paul B Manning, Perceptive Advisors Llc and Ted White.
View institutional ownership trends
.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $5.32.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals (NASDAQ:VRCA) has a market capitalization of $223.21 million and generates $8.64 million in revenue each year. The company earns $-24,490,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The official website for the company is www.verrica.com. The company can be reached via phone at (434) 453-3300 or via email at info@verrica.com.

This page (NASDAQ:VRCA) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -